Azab 500 Parth


Manufacturer: Parth Substance: Azithromycin Pack: 500mg 3 pills

Categories: , Tag:

Additional information




Azab 500 by Parth is an antibacterial drug of a wide spectrum of action from the group of macrolides-azalides, acts bacteriostatically. Linking to the 50S subunit of ribosomes, inhibits peptidranslokase at the stage of translation, suppresses protein synthesis, slows the growth and multiplication of bacteria, has a bactericidal effect at high concentrations. It acts on extra- and intracellularly located pathogens.
Microorganisms can be initially resistant to antibiotic action or can acquire resistance to it.

Mechanism of action

Azithromycin is a broad-spectrum antibiotic, the first representative of a new subgroup of macrolide antibiotics called azalides. The molecule is constructed by adding an oxygen atom to the lactone ring of erythromycin A. The chemical name of azithromycin is 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A. The molecular weight is 749.0.

The mechanism of action of azithromycin is binding to the 50 S unit of the ribosome, which prevents the synthesis of bactericidal proteins and the translocation of peptides.

The mechanism of resistance

Resistance to azithromin may be natural or acquired. Three main mechanisms of resistance in bacteria: alteration of the target side, alteration in antibiotic transport and modification of the antibiotic.

Complete cross-resistance exists between the following microorganisms: Sreptococcuspneumoniae, beta-hemolytic streptococcus of group A, Enterococcusfaecalis and Staphylococcusaureus, including methicillin, resistant Saureus (MRSA) to erythromycin, azithromycin, other macrolides and lincosamides.

Drug Interactions

  • Antacids (aluminum and magnesium-containing), ethanol and food slow down and reduce absorption. With the co-administration of warfarin and azithromycin (in usual doses) no changes in prothrombin time have been detected, however, considering that the interaction of macrolides and warfarin may enhance the anticoagulation effect, patients need careful monitoring of prothrombin time.
  • Digoxin: increased digoxin concentration.
  • Ergotamine and dihydroergotamine: intensification of toxic effects (vasospasm, dysesthesia).
  • Triazolam: reduced clearance and increased pharmacological action of triazolane. Slows down the excretion and increases the plasma concentration and toxicity of cycloserine, indirect anticoagulants, methylprednisolone, felodipine, and LS undergoing microsomal oxidation (carbamazepine, terfenadine, cyclosporine, hexobarbital, ergot alkaloids, valproic acid, disopyramide, bromocriptine phenytoin, phenytoin, oral hypoglycemic agents, theophylline and other xanthine derivatives) – due to the inhibition of microsomal oxidation in hepatocytes with azithromycin).
  • Lincosamines: weaken the effectiveness, tetracycline and chloramphenicol – strengthen. Pharmaceutically incompatible with heparin.

Related Products